Odanacatib, a Selective Cathepsin K Inhibitor, Demonstrates Comparable Pharmacodynamics and Pharmacokinetics in Older Men and Postmenopausal Women

Abstract

Although the primary hypothesis was not met, there were no clinically meaningful differences in PD, PK, or PK/PD parameters between older men and postmenopausal women, supporting further research on odanacatib (50 mg once weekly) as a treatment for male osteoporosis. Odanacatib was generally well tolerated.